Spot on, Moderna. This is exactly the billion dollar question. If the CMML trial is outsourced but HGEN now owns the IP and Lenz, why are the assets being sold. All that is in the SC&H declaration is that-we think this is the best alternative. Except that strategy was based upon data prior to release of the interim results which had the potential of being a game changer, according to the lead investigator. As shareholders, we should be concerned as to why this is being done instead of a royalty agreement and as an expedited Section 363. Simply, this is wrong. We may not have the capability to run multiple trials, at this point, but we clearly know the approval process could begin relatively soon with consistent results. And if the current CEO is not committed to the program under reduced pay, we'll find someone else.
This would be in the interest of employees, creditors and shareholders. Not the transfer of the assets for a pittance.
Market Data 
Markets 
AI
